Literature DB >> 16762758

Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy.

Paul Sorajja1, Rick A Nishimura, Steve R Ommen, Michael J Ackerman, A Jamil Tajik, Bernard J Gersh.   

Abstract

We examined the 10-year outcome of 107 patients with hypertrophic cardiomyopathy and massive myocardial hypertrophy as assessed by echocardiography. These patients demonstrated excess mortality in comparison with their expected survival with respect to a general population of individuals (10-year survival 77% vs 95%, P < .001). Adverse events occurred primarily in the youngest and oldest patients. Sudden cardiac death was the most frequent cause of death among the young (overall survival 80%), whereas other causes predominated in older patients (overall survival 31%). For patients aged 30 to 59 years, survival was 97%, no different from their expected survival. Patients with hypertrophic cardiomyopathy and massive hypertrophy identified by echocardiography are at increased risk of death, but this risk is related to age at presentation. Sudden cardiac death is the primary cause in those who are young, whereas other causes predominate in older patients. Middle-aged patients with massive hypertrophy do not experience an excess mortality.

Entities:  

Mesh:

Year:  2006        PMID: 16762758     DOI: 10.1016/j.echo.2006.01.005

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  8 in total

Review 1.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

Review 2.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

3.  Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?

Authors:  G Neal Kay
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

4.  RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy.

Authors:  Beth D Kaufman; Scott Auerbach; Sushma Reddy; Cedric Manlhiot; Liyong Deng; Ashwin Prakash; Beth F Printz; Dorota Gruber; Dimitrios P Papavassiliou; Daphne T Hsu; Amy J Sehnert; Wendy K Chung; Seema Mital
Journal:  Hum Genet       Date:  2007-09-13       Impact factor: 4.132

Review 5.  Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy.

Authors:  Alyson Kelley-Hedgepeth; Martin S Maron
Journal:  Curr Heart Fail Rep       Date:  2009-09

6.  Midterm Outcome After Septal Myectomy and Medical Therapy in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy.

Authors:  Jiejun Sun; Lin Liang; Peijin Li; Tengyong Jiang; Xianpeng Yu; Changwei Ren; Ran Dong; Jiqiang He
Journal:  Front Cardiovasc Med       Date:  2022-03-25

7.  Women with hypertrophic cardiomyopathy have worse survival.

Authors:  Jeffrey B Geske; Kevin C Ong; Konstantinos C Siontis; Virginia B Hebl; Michael J Ackerman; David O Hodge; Virginia M Miller; Rick A Nishimura; Jae K Oh; Hartzell V Schaff; Bernard J Gersh; Steve R Ommen
Journal:  Eur Heart J       Date:  2017-12-07       Impact factor: 29.983

Review 8.  Heart failure in sub-Saharan Africa.

Authors:  Gerald S Bloomfield; Felix A Barasa; Jacob A Doll; Eric J Velazquez
Journal:  Curr Cardiol Rev       Date:  2013-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.